Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

As a leading charitable patient assistance foundation, PAN’s role in accelerating access to care goes beyond providing critical financial assistance to patients in over 80 disease areas.

Eli Lilly and Company (NYSE:LLY) is one of the 12 stocks that will make you rich in 10 years. On June 23, Truist Securities reiterated its “Buy” rating on Eli Lilly stock.

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin drug strategy.

Ten charts illustrate the extraordinary level of support the United States has provided Ukraine in its war against Russian invaders.